Columbia Laboratories, Inc. (Nasdaq: CBRX) and Watson Pharmaceuticals, Inc. (NYSE: WPI) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Columbia's New Drug Application (NDA) for PROCHIEVE® (progesterone gel) for the reduction of risk of preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy. The acceptance of the NDA for filing means FDA has determined that the application is sufficiently complete to permit a substantive review... ![](/proxy.php?image=http%3A%2F%2Ffeedads.g.doubleclick.net%2F%7Ea%2FvSAiHLPceGybcfJ-df-FlcUIAFI%2F0%2Fdi&hash=5a38b75a5f624eed5a1aa9530268b5db)
![](/proxy.php?image=http%3A%2F%2Ffeedads.g.doubleclick.net%2F%7Ea%2FvSAiHLPceGybcfJ-df-FlcUIAFI%2F1%2Fdi&hash=f8bfb19a07f7ccb381713556e6b1b08d)
More...
More...